Summit Therapeutics (NASDAQ: SMMT)
$20.62
(-3.3%)
-$0.70
Price as of June 27, 2025, 3:58 p.m. ET
Summit Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Summit Therapeutics Company Info
Summit Therapeutics, Inc. a biopharmaceutical company, which discovers, develops, and commercializes medicines to treat infectious diseases. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Menlo Park, CA.
News & Analysis
The Fool has written over 100 articles on Summit Therapeutics.
Featured Article
Why Summit Therapeutics Stock Tanked Today
Eric Volkman | Jun 11, 2025
Featured Article
2 Soaring Stocks Wth More Upside Potential
Prosper Junior Bakiny | Jun 5, 2025
Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy?
Cory Renauer | Jun 2, 2025
Why Summit Therapeutics Plunged Today
Billy Duberstein | May 30, 2025
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Keith Speights | May 21, 2025
Can Summit Therapeutics Stock Double Your Money?
David Jagielski | May 7, 2025
This Soaring Stock Just Delivered More Good News. Time to Buy?
Prosper Junior Bakiny | May 2, 2025
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today
Billy Duberstein | Apr 25, 2025
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.